Portfolio Companies

Affini-T orchestrates the immune system to target oncogenic driver mutations to deliver transformative therapies intended to cure patients.

Developing novel therapies for patients with rare bone and connective tissue disorders.

Developing a proprietary platform which leverages novel parvoviruses that have been pressure tested by nature to target specific tissues, carry a larger cargo, with minimal neutralizing immunity and the potential to re-dose.

Developing first-in-class CAR-macrophage platform for oncology and non-oncology applications.

Developing treatments derived from proprietary discovery platform for CNS disorders and neurodegenerative diseases.

Cyrus solves difficult protein engineering and structure prediction problems using the most scientifically advanced, powerful, and laboratory-proven software.

Went public in 2021 and was formerly NSDQ:DICE before an acquisition by Lilly for $2.4B. Developing innovative medicines in immunology.

Harnessing the immune system for improved patient outcomes using a targeted approach.

Overcoming the challenge of intracellular target access to transform the treatment of devastating diseases.

Drugging transcription factor complexes through novel pockets, or ‘switch sites’, for cancer.

Minimal residual disease testing platform.

Pioneering the most comprehensive multiomics platform for early cancer detection.

Developing best-in-class protein degraders for autoimmune diseases

Broadly applicable biologics platform across  many different therapeutic areas.

Acquired by Ipsen in a total deal worth €1B with a €350M upfront payment. Exploring uncharted territories in immunomodulation comprising Butyrophilins & Gamma-delta T cells.

Developing targeted therapeutics for complex diseases using novel single cell analyses.

Acquired by Kite, a Gilead company, for $350M. Gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene delivery.

Biotechnology company developing antibody-based therapeutics to halt fibrosis in a variety of organ systems.

Discovering breakthrough gene editing systems for curing disease.

Developing animal-free cell culture media supplements for biopharmaceutical companies.

Acquired by BMS for $1.5B. circRNA platform company for next-generation therapies and vaccines.

Developing therapeutics for rare cancers, including anaplastic astrocytoma.

Went public in 2018 and was formerly NSDQ:ORTX before an acquisition by Kyowa Kirin for $0.5B. Developing gene therapies for rare immunology disorders.

Developing therapeutics for rare dermatological disorders.

Targeting a range of fibrotic diseases, with a focus on fibrotic tissue-specific inhibition of integrins.

Gene-editing platform to overcome cancers, cure genetic diseases, and enable development of safer food.

Synthetic biology and manufacturing company developing next-generation solutions for new therapeutics and vaccines.

Charting a course to therapeutics for difficult-to-treat cancers.

Developing targeted biotherapeutics that rebalance the immune system.

Small molecule platform company for alternative modulation of RNA.

Innovation engine for novel antibody therapies

Developing novel therapeutics for autoimmune diseases through the modulation of regulatory T cells

Applying an all-in-human, artificial intelligence powered drug discovery platform to unlock new drugs at scale.

Overcoming current limitations of CAR-T cell therapeutics by using combining cell and gene editing technologies that address unmet patient need.

Bringing best-in-class immune-based therapies to patients in need.